Neoplasms and Hemic and Lymphatic Diseases

At Hospital Universitario Lucus Augusti in Lugo, the oncology program is centered on studies in breast cancer, lung cancer, melanoma, ovarian cancer, and bladder cancer. These trials are mainly designed to test new treatment combinations, compare them with current standards, and measure outcomes such as survival and relapse control.

  • Research in metastatic non-small cell lung cancer, including EGFR-mutant disease, focuses on whether new immunotherapy-based combinations can improve overall survival and progression-free survival.
  • Studies in early breast cancer and invasive breast cancer are examining long-term outcomes and the value of updated endocrine treatment strategies.
  • Melanoma and high-risk non-muscle invasive bladder cancer trials are evaluating whether adding immunotherapy can better prevent recurrence or progression.
  • Additional work includes treatment research in advanced epithelial ovarian cancer, aiming to improve disease control with modern combination therapy.

This portfolio shows a strong focus on refining cancer care across solid tumors, with an emphasis on improving survival, delaying recurrence, and identifying more effective options for patients with advanced or high-risk disease.

Male Urogenital Diseases

The site also conducts focused research in prostate cancer, especially metastatic castration-resistant prostate cancer and aggressive variants of the disease. These studies are intended to assess whether newer drug combinations can better control tumor growth and extend progression-free survival.

  • Trials in metastatic castration-resistant prostate cancer are testing novel targeted and immunotherapy-based approaches against current treatment options.
  • Research in aggressive variant metastatic castration-resistant prostate cancer is exploring combination regimens to improve disease control in a more difficult-to-treat population.
  • Work in high-risk non-muscle invasive bladder cancer links this therapeutic area with urologic oncology, with a goal of reducing recurrence and delaying progression.

This activity highlights a clear interest in improving outcomes for advanced urologic cancers through better treatment strategies and more durable disease control.

Respiratory Tract Diseases

In respiratory research, Hospital Universitario Lucus Augusti is involved in studies on non-small cell lung cancer and severe eosinophilic asthma. The trials aim to improve both cancer treatment and symptom control by evaluating therapies that may offer better survival or reduce flare-ups and progression.

  • Non-small cell lung cancer studies include patients with metastatic disease and those with ALK-rearranged tumors, with a focus on extending survival after standard treatment.
  • Trials in severe eosinophilic asthma are assessing whether new therapy can reduce the frequency of serious exacerbations and improve long-term disease management.
  • Several lung cancer projects are comparing emerging combinations with established regimens to see which approach provides better disease control.

Overall, the respiratory portfolio combines advanced oncology research with chronic airway disease studies, reflecting a broad effort to improve outcomes in both malignant and non-malignant lung conditions.

Hematologic Disease Research

The hematology and hemotherapy department also contributes to studies in myelofibrosis, a serious blood cancer that affects the bone marrow and blood-forming system. The main goal is to test whether new treatment combinations can improve symptom control and disease response compared with current care.

  • Research in myelofibrosis is evaluating combination therapy for patients who are treatment-naïve, with attention to efficacy and overall disease management.
  • These studies aim to determine whether newer approaches can offer better control of the underlying hematologic malignancy and improve patient outcomes.

This area adds an important blood-disorder focus to the site’s broader research profile, complementing its strong activity in solid tumor trials.